CNTB · Connect Biopharma Holdings Ltd · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | $3.2M | — | — | — | |
| $73.37M | $58.14M | $48.49M | $69.06M | — | — | |
| $1.62M | $2.79M | $7.05M | $7.07M | — | — | |
| -$68.58M | -$55.01M | -$16.29M | -$62.37M | — | — | |
| USD/shares | -$1.19 | -$1.00 | -$0.28 | -$1.13 | -$2.15 | -$3.88 |
| USD/shares | -$1.19 | -$1.00 | -$0.28 | -$1.13 | -$2.15 | -$3.88 |
| shares | — | 55.66M | 55.21M | 55.07M | — | — |
| shares | — | 55.66M | 55.21M | 55.07M | — | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 309 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Treatment of Respiratory Diseases Segment | $64,000 | $26,033,000 | $0 |